If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin® Therapies
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mLHumulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mLHumulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mLHumulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Why are the 3 mL vials of Humulin® 70/30 and Humulin® N (isophane insulin human) being discontinued?
The decision to discontinue manufacturing the 3 mL vials of Humulin 70/30 and Humulin N was made after careful consideration of demand and manufacturing capabilities to better align to our current and future customer needs and preferences.
Discontinuation of 3 mL Vials
Eli Lilly and Company has decided to discontinue manufacturing the 3 mL vials of Humulin® 70/30 (human insulin isophane suspension and human insulin injection [HI70/30]), and Humulin® N (isophane insulin human suspension [NPH]) as of March 7, 2022.1
The decision to discontinue the 3 mL vials of HI70/30 and NPH was made after careful consideration of demand and manufacturing capabilities to better align to our current and future customer needs and preferences.1
Based on the current supply, we anticipate the supply will be diminished by
- May 2023 for 3 mL vials of HI70/30, and
- September 2022 for 3 mL vials of NPH.1
To hospitals, health systems and patients, HI70/30 and NPH will continue to be available in 10 mL vials and 3 mL KwikPen®.1
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: March 05, 2025